Arca
Skip to content
Tools
Tools

Label Changes: Imdelltra (tarlatamab-dlle)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Imdelltra label DailyMed has published, from Amgen, Inc, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 5
  • Sections changed, version 7 to 8: 6

What changed from version 7 to version 8

Jul 20, 2026 to Sep 25, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged · 39 words added, 27 removed
  2. Warnings and precautionsChanged · 23 words added, 9 removed
  3. Adverse reactionsChanged · 20 words added, 4 removed
  4. Patient counseling informationChanged · 21 words added, 2 removed
  5. Medication guideChanged · 139 words added, 111 removed
  6. Untitled sectionChanged · 2 words added, 2 removed

Dosage and administration

Changed39 words added, 27 removed
6 unchanged lines
IMDELLTRA should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions, such as CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS) [see Warnings and Precautions (5.1, 5.2)].
Due to the risk of CRS and neurologic toxicity, including ICANS, monitor patients from the start of the IMDELLTRA infusion for 226 to 248 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting [see Dosage and Administration (2.5) and Warnings and Precautions (5.1, 5.2)].
Perform patient assessment including vital signs check on Cycle 1 Days 2 and 9.
Recommend patients to remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from start of the infusion with IMDELLTRA following Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver.
2 unchanged lines
Administer IMDELLTRA as an intravenous infusion for one hour.
The recommended step-up dose and schedule for IMDELLTRA is provided in Table 1. Administer step-up dose and schedule on Cycle 1 Day 1 to reduce the incidence and severity of CRS.
After step-up dose and schedule on Cycle 1 Day 115, administer IMDELLTRA every 2 weeks until disease progression or unacceptable toxicity.
Table 1. Recommended Dose and Schedule of IMDELLTRA
1 unchanged line
Note: See Table 4 for recommendation on restarting IMDELLTRA after dose delays.
Step-up Dose and Schedule Cycle 1 | Day 1 | Step-up dose 1 mg | Administer IMDELLTRA as a 1-hour intravenous infusion in an appropriate healthcare setting. | Monitor patients from the start of the IMDELLTRA infusion for 226 to 248 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Perform patient assessment including vital signs check on Cycle 1 Days 2 and 9. Recommend that patients remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from start of the IMDELLTRA infusion accompanied by a caregiver.
Day 8 | 10 mg
29 unchanged lines
2.5 IMDELLTRA Dosage Modifications and Adverse Reaction Management
No dose reduction for IMDELLTRA is recommended. See Table 5 and Table 6 for recommended management of CRS, neurologic toxicity including ICANS, respectively, and Table 7 for cytopenias, infections and other adverse reactions.
Cytokine Release Syndrome (CRS)
1 unchanged line
If CRS is suspected, manage according to the recommendations in Table 5. Monitor patients who experience Grade 2 or higher CRS (e.g., hypotension not responsive to fluids, or hypoxia requiring supplemental oxygen) with continuous cardiac telemetry and pulse oximetry.
For severe or life-threatening CRS, recommend administering tocilizumab or equivalent therapy and intensive monitoring (e.g., ICU) for supportive therapy. Perform laboratory testing to monitor for disseminated intravascular coagulation (DIC), hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function. Table 5 provides the guidelines for grading and dosage modification and management of cytokine release syndrome.
Table 5. Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
1 unchanged line
Grade 1 | Symptoms require symptomatic treatment only (e.g., fever ≥ 100.4°F without hypotension or hypoxia). | Withhold IMDELLTRA until event resolves, then resume IMDELLTRA at the next scheduled dose . | Administer symptomatic treatment (e.g., acetaminophen) for fever. Consider dexamethasone 4 mg to 10 mg oral or IV (or equivalent) .
Grade 2 | Symptoms require and respond to moderate intervention. Fever ≥ 100.4°F, Hypotension responsive to fluids not requiring vasopressors and/or Hypoxia requiring low flow nasal cannula or blow-by. | Withhold IMDELLTRA until event resolves, then resume IMDELLTRA at the next scheduled dose. | Recommend hospitalization for a minimum of 24 hours with cardiac telemetry and pulse oximetry. Administer symptomatic treatment (e.g., acetaminophen) for fever. Administer supplemental oxygen and intravenous fluids when indicated. Consider dexamethasone (or equivalent) 8 mg oral or IV. Consider tocilizumab (or equivalent). When resuming the next planned dose, monitor patients from the start of the IMDELLTRA infusion for 226 to 248 hours in an appropriate healthcare setting. Consider tocilizumab.
Grade 3 | Severe symptoms defined as temperature ≥ 100.4°F with: Hemodynamic instability requiring a vasopressor (with or without vasopressin) and/or Worsening hypoxia or respiratory distress requiring high flow nasal cannula (> 6 L/min oxygen) or face mask. | Withhold IMDELLTRA until the event resolves, then resume IMDELLTRA at the next scheduled dose. For recurrent Grade 3 events, permanently discontinue IMDELLTRA. | In addition to Grade 2 treatment: Recommend intensive monitoring, e.g., ICU care. Administer dexamethasonecdexamethasone (or equivalent) 8 mg IV every 8 hours up to 3 doses. Vasopressor support as needed. High flow oxygen support as needed. Recommend tocilizumab (or equivalent). Prior to the next dose, administer concomitant medications as recommended for Cycle 1 Day 1 and Cycle 1 Day 8 (see Table 3). When resuming the next planned dose, monitor patients from the start of the IMDELLTRA infusion for 22 to 24 hours in an appropriate healthcare setting.
Grade 4 | Life-threatening symptoms defined as temperature ≥ 100.4°F with: Hemodynamic instability requiring multiple vasopressors (excluding vasopressin). and/or Worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure. | Permanently discontinue IMDELLTRA. | ICU care. Per Grade 3 treatment. Recommend tocilizumab (or equivalent).
Neurologic Toxicity including ICANS
74 unchanged lines
Prepared IMDELLTRA Infusion Bag | 8 hours | 7 days
Discard the prepared IMDELLTRA infusion bag after maximum storage time (from time of reconstitution). If refrigerated, allow the prepared IMDELLTRA infusion bag to come to room temperature prior to administration, and complete the infusion within 8 hours (including preparation and infusion time). Do not re-refrigerate prepared infusion bag.

Warnings and precautions

Changed23 words added, 9 removed
5 WARNINGS AND PRECAUTIONS
5.1 Cytokine Release Syndrome (CRS)
IMDELLTRA can cause cytokine release syndrome (CRS) including life-threatening or fatal reactions.
3 unchanged lines
Administer IMDELLTRA following the recommended step-up dosing and administer concomitant medications before and after Cycle 1 Day 1 and Cycle 1 Day 8 IMDELLTRA infusions as described in Table 3 to reduce the risk of CRS [see Dosage and Administration (2.3)]. Administer IMDELLTRA in an appropriate healthcare facility equipped to monitor and manage CRS. Ensure patients are well hydrated prior to administration of IMDELLTRA.
Closely monitor patients for signs and symptoms of CRS during and after treatment with IMDELLTRA. At the first sign of CRS during treatment, immediately discontinue IMDELLTRA infusion. If CRS occurs during or after treatment, evaluate the patient for hospitalization and institute supportive caremanage based on severity [see Dosage and Administration (2.5)]. Withhold or permanently discontinue IMDELLTRA based on severity [see Dosage and Administration (2.5)]. Counsel patients and caregivers to seek immediate medical attention should signs or symptoms of CRS occur after discharge.
5.2 Neurologic Toxicity Including ICANS
1 unchanged line
In the pooled safety population [see Adverse Reactions (6.1)], neurologic toxicity occurred in 65% of patients who received IMDELLTRA, with Grade 3 or higher events in 7% of patients including fatal events in 0.2%. The most frequent neurologic toxicities were dysgeusia (34%), headache (17%), peripheral neuropathy (9%), dizziness (9%), and insomnia (8%).
The incidence of signs and symptoms consistent with ICANS was 10% in IMDELLTRA- treated patients, including events with the preferred terms: ICANsICANS (4.7%), muscular weakness (3.2%), cognitive disorder (0.6%), aphasia (0.6%), depressed level of consciousness (0.4%), seizures (0.4%), encephalopathy (0.4%), and leukoencephalopathy (0.2%). There was one fatal reaction of ICANS [see Adverse Reactions (6.1)]. Recurrent ICANS occurred in 1.5% of patients. Of the patients who experienced ICANS, most experienced the event following Cycle 1 Day 1 (2.5%) and Cycle 1 Day 8 (3.6%). Following Day 1, Day 8, and Day 15 infusions, 1.3%, 1.3% and 0.4% of patients experienced Grade ≥ 2 ICANS, respectively. ICANS can occur several weeks following administration of IMDELLTRA. The median time to onset of ICANS from the first dose of IMDELLTRA was 16 days (range: 1 to 862 days). The median time to resolution of ICANS was 4 days (range: 1 to 40 days).
The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Clinical signs and symptoms of ICANS may include but are not limited to confusional state, depressed level of consciousness, disorientation, somnolence, lethargy, and bradyphrenia.
4 unchanged lines
IMDELLTRA can cause cytopenias including neutropenia, thrombocytopenia, and anemia.
In the pooled safety population, [see Adverse Reactions (6.1)], based on laboratory data, decreased neutrophils occurred in 16% of patients, including 9% Grade 3 or 4. The median time to onset for Grade 3 or 4 decreased neutrophil count was 41 days (range: 2 to 306 days). Decreased platelets occurred in 30%, including 2.2% Grade 3 or 4. The median time to onset for Grade 3 or 4 decreased platelets was 67 days (range: 3 to 420 days). Decreased hemoglobin occurred in 56% of patients, including 4.7% Grade 3 or 4.
Febrile neutropenia was reported as an adverse event in 1.5% of patients treated with IMDELLTRA.
3 unchanged lines
IMDELLTRA can cause serious infections, including life-threatening and fatal infections.
In the pooled safety population, [see Adverse Reactions (6.1)], infections including opportunistic infections occurred in 43% of patients who received IMDELLTRA, including 14% Grade 3 or 4. The most frequent infections were pneumonia (11%), urinary tract infection (9%), COVID-19 (6%), upper respiratory tract infection (4.7%), respiratory tract infection (4%), candida infection (2.1%), oral candidiasis (2.1%) and nasopharyngitis (2.1%).
Monitor patients for signs and symptoms of infection prior to and during treatment with IMDELLTRA and treat as clinically indicated. Withhold or permanently discontinue IMDELLTRA based on severity [see Dosage and Administration (2.5)].
1 unchanged line
IMDELLTRA can cause hepatotoxicity.
In the pooled safety population [see Adverse Reactions (6.1)], based on laboratory data, elevated ALT occurred in 39% of patients who received IMDELLTRA, including 2.5% Grade 3 or 4 ALT. Elevated AST occurred in 43% of patients, including 3.2% Grade 3 or 4. Elevated bilirubin occurred in 16% of patients, including 1.3% Grade 3 or 4 [see Adverse Reactions (6.1)]. Liver enzyme elevation can occur with or without concurrent CRS.
Monitor liver enzymes and bilirubin prior to treatment with IMDELLTRA, and as clinically indicated. Withhold IMDELLTRA or permanently discontinue based on severity [see Dosage and Administration (2.5)].
6 unchanged lines

Adverse reactions

Changed20 words added, 4 removed
11 unchanged lines
Extensive Stage Small Cell Lung Cancer
The safety of IMDELLTRA was evaluated in 252 patients in DeLLphi-304, a multicenter, randomized, open label trial in patients with extensive stage small cell lung cancer (ES- SCLC) with disease progression following treatment with platinum-based chemotherapy with or without an anti-PD-(L)1 antibody [see Clinical Studies (14.1)]. Patients received IMDELLTRA (n=252) or investigator's choice or investigator's choice of topotecan [n=176], lurbinectedin [n=45] or amrubicin [n=23].
Among patients who received IMDELLTRA, 41% were exposed for 6 months or longer and 18% were exposed for greater than one year.
52 unchanged lines
Permanent discontinuation of IMDELLTRA due to an adverse reaction occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of IMDELLTRA in >1% of patients included cytokine release syndrome (1.6%) and tumor lysis syndrome (1.1%).
Dosage interruptions of IMDELLTRA due to an adverse reaction occurred in 27% of patients. Adverse reactions which required dosage interruption in ≥ 2% of patients included fatigue (3.2%), cytokine release syndrome (2 .7%) and respiratory tract infection (2.1%).
Table 15 summarizes adverse reactions observed in DeLLphi-300 and DeLLphi-301.
19 unchanged lines
Cough | 17 | 0
Table 16 summarizes laboratory abnormalities in DeLLphi-300 and DeLLphi-301.
Table 16. Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with ES - SCLC in DeLLphi-300 and DeLLphi-301
| IMDELLTRA
17 unchanged lines

Patient counseling information

Changed21 words added, 2 removed
3 unchanged lines
Inform patients and their caregivers of the risk of CRS, and to immediately contact their healthcare provider for signs and symptoms associated with CRS including pyrexia, hypotension, fatigue, tachycardia, headache, hypoxia, nausea and vomiting [see Warnings and Precautions (5.1)].
Advise patients that they should be monitored from the start of the IMDELLTRA infusion for 226 to 248 hours on Cycle 1 Day 1 and Cycle 1 Day 8 doses in an appropriate healthcare setting [see Warnings and Precautions (5.1)].
Advise patients that an assessment including vital signs check will be performed on Cycle 1 Days 2 and 9.
Advise patients to remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from start of the infusion with IMDELLTRA following Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver.
Neurologic Toxicity Including Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Discuss the signs and symptoms associated with ICANS with patients and their caregivers. Advise patients to immediately contact their healthcare provider if they experience any signs or symptoms of ICANS, such as encephalopathy, confusion, delirium, seizure, ataxia, weakness or numbness of arms and legs, tremor, and headache.
13 unchanged lines

Medication guide

Changed139 words added, 111 removed
MEDICATION GUIDE IMDELLTRA® (im del trah) (tarlatamab-dlle) for injection, for intravenous use
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 1109/20252026
What is the most important information I should know about IMDELLTRA? IMDELLTRA can cause serious side effects, including:
Cytokine Release Syndrome (CRS). CRS is common duringIMDELLTRA treatmentcan withcause IMDELLTRACRS andthat can also be severe, life-threatening, or cause death. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:
| fever of 100.4°F (38°C) or higher low blood pressure tiredness fast heartbeat or dizziness headache shortness of breath or trouble breathing | nausea and vomiting confusion, restlessness, or feeling anxious problems with balance and movement, such as trouble walking heart, liver, or kidney problems blood clots or unusual bleeding or bleeding that lasts a long time
3 unchanged lines
| changes in taste headache numbness or tingling of your hands or feet dizziness trouble sleeping muscle weakness or numbness of arms or legs problems with walking, or loss of balance or coordination | trouble speaking, memory loss, or personality changes confusion, feeling disoriented, slow thinking, or not being able to think clearly fainting or loss of consciousness seizures shaking (tremors) sleepiness feeling like you have no energy
Due to the risk of CRS and neurologic problems you will receivebe themonitored followingas monitoringfollows during treatment with IMDELLTRA treatment: ForCycle 1 Day 1 and Day 8 of Cycle 1 doses,: your healthcare provider will monitor you for 226 to 248 hours from the start of theyour IMDELLTRA infusioninfusions in an appropriate healthcare setting that can manage thesepossible side effects. Youyou should remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from the start of the IMDELLTRA infusion after your Day 1 and Day 8 of Cycle 1IMDELLTRA dosesinfusions and be accompanied by a caregiver. For Day 15 of Cycle 12 and Cycle 2Day doses9, your healthcare provider will watchcheck you for 6any tosigns 8or hourssymptoms, afterincluding thechecking IMDELLTRAyour infusion.temperature, Forbreathing, Cycleheart 3rate, blood pressure, and Cycleoxygen 4levels. dosesDay 15 dose, your healthcare provider will watch you for 36 to 48 hours after the IMDELLTRAyour infusion. For Cycle 5 and later2 doses, your healthcare provider will watch you for 26 to 8 hours after the IMDELLTRAyour infusion. YourCycle 3 and Cycle 4 doses, your healthcare provider will monitorwatch you for signs3 andto symptoms4 ofhours CRSafter andyour neurologicinfusion. problemsCycle during5 treatmentand withlater IMDELLTRAdoses, andyour treathealthcare provider will watch you asfor needed.2 Youhours mayafter beyour hospitalizedinfusion. ifIf you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA., Youryour healthcare provider maywill temporarilytreat stopyou oras completelyneeded, stopyou yourmay treatmentneed withto be hospitalized, and your IMDELLTRA iftreatment youmay developbe CRStemporarily or neurologiccompletely problemsstopped. See "What are the possible side effects of IMDELLTRA?" for more information about side effects.
What is IMDELLTRA? IMDELLTRA is a prescription medicine used to treat adults with extensive stage small cell lung cancer (ES-SCLC), which is cancer that has spread throughout the lung or to other parts of the body, and who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working. It is not known if IMDELLTRA is safe and effective in children.
Before receiving IMDELLTRA, tell your healthcare provider about all of your medical conditions, including if you: have an infection are pregnant or plan to become pregnant. IMDELLTRA may harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with IMDELLTRA. You should use an effective form of birth control (contraception) during treatment with IMDELLTRA, and for 2 months after your last dose of IMDELLTRA. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with IMDELLTRA. are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA passes into your breast milk. Do not breastfeed during treatment with IMDELLTRA and for 2 months after the last dose of IMDELLTRA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive IMDELLTRA? IMDELLTRA will be given to you by your healthcare provider by intravenous (IV) infusion through a needle placed in a vein. The infusion will take about 1 hour. Your IMDELLTRA treatment schedule is divided into cycles that are usually 28 days (4 weeks) long. In Cycle 1, you will receive 3 doses of IMDELLTRA (Days 1, 8, and 15). After Cycle 1, you will receive 2 doses of IMDELLTRA each cycle (Days 1 and 15). Your healthcare provider will decide how many treatment cycles you will receive. See "What is the most important information I should know about IMDELLTRA?" for more information about how you will receive IMDELLTRA.
What should I avoid while receiving IMDELLTRA? Do not drive, operate heavy or potentially dangerous machinery or do other dangerous activities, including work-related activities, during treatment with IMDELLTRA if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. See " What is the most important information I should know about IMDELLTRA " for more information about signs and symptoms of neurologic problems.
6 unchanged lines
Your healthcare provider will do bloodwork before you start and during treatment with IMDELLTRA. Your healthcare provider will monitor you for signs or symptoms of these serious side effects during treatment and may temporarily or completely stop treatment with IMDELLTRA if you develop certain serious side effects. The most common side effects of IMDELLTRA also include:
CRS tiredness decreased appetite a bad or metallic taste in your mouth | fever |constipation muscle or bone pain constipation nausea
The most common severe abnormal blood test results with IMDELLTRA include: decreased white blood cells, decreased sodium, and increased uric acid. These are not all of the possible side effects of IMDELLTRA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of IMDELLTRA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about IMDELLTRA that is written for health professionals.
What are the ingredients in IMDELLTRA? Active ingredients: tarlatamab-dlle Inactive ingredients: glutamic acid, polysorbate 80, sucrose, and sodium hydroxide. Inactive ingredients of IV Solution Stabilizer: citric acid monohydrate, lysine hydrochloride, polysorbate 80, sodium hydroxide and water for Injection. Manufactured by: Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 U.S. License No. 1080 © 2024-20252026 Amgen Inc. All rights reserved. V2V3 For more information, go to www.imdelltra.com or call Amgen at 1-800-772-6436.

Untitled section

Changed2 words added, 2 removed
1 unchanged line
Manufactured by: Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 U.S.A. U.S. License No. 1080 Patent: http://pat.amgen.com/imdelltra/
© 2024 - 20252026 Amgen Inc. All rights reserved.
1XXXXXX - V2V3

Unchanged: Boxed warning, Indications and usage, Dosage forms and strengths, Contraindications, Use in specific populations, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, PRINCIPAL DISPLAY PANEL - Kit Carton - 1 mg/vial, PRINCIPAL DISPLAY PANEL - Kit Carton - 10 mg/vial.

Every version

5 versions of set 1e7b6163-5d83-42ea-82c9-cf7620cdc782, newest first.
VersionPublished on DailyMedCompareSPL file
8Sep 25, 2026Shown belowDownload .zip
7Jul 20, 2026With version 5Download .zip
5Dec 4, 2025With version 3Download .zip
3Jul 18, 2024With version 2Download .zip
2May 22, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.